Clinical Trials Sponsored by AztraZeneca

Total 4314 results

University of KwaZulu
AstraZeneca; Medical Research Council, South Africa

Unknown

Paediatric and Adult African Spirometry II (PAASII)

Lung Diseases

South Africa
Foundation for Atlanta Veterans Education and Research...
AstraZeneca

Completed

Effect of Crestor on Lipoprotein Metabolism in Humans

Hypercholesterolemia

United States
Lyudmila Bazhenova, M.D.
AstraZeneca

Terminated

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Unknown

Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus (ROCOCO)

Carcinoma of the Oesophagus

United Kingdom
Grupo Gallego de Cancer de Pulmon
AstraZeneca; Dynamic Solutions

Unknown

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Metastatic Non-Small-Cell Lung Cancer

Spain
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
Finnish Breast Cancer Group
Sanofi; Hoffmann-La Roche; AstraZeneca

Completed

Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

Breast Cancer

Finland
University of Manitoba
AstraZeneca; Manitoba Medical Service Foundation; CancerCare Manitoba

Recruiting

Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer (OPERARADIO)

Esophageal Cancer

Canada
European Organisation for Research and Treatment...
AstraZeneca

Withdrawn

Chemo-free BRCA-targeted Neoadjuvant Strategy

BRCA1 Mutation | BRCA2 Mutation | TNBC - Triple-Negative Breast Cancer
Botswana Harvard AIDS Institute Partnership
AstraZeneca; Botswana Ministry of Health

Completed

Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2

COVID-19

Botswana
University Hospital Southampton NHS Foundation...
AstraZeneca; Cancer Research UK

Completed

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy (ProCAID)

Prostate Cancer

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; University of Cambridge

Terminated

A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems (PRIME)

Drug-Related Side Effects and Adverse Reactions | Cardiovascular System Disease

United Kingdom
CCTU- Cancer Theme
AstraZeneca

Active, not recruiting

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer (PORTICO-SABR)

Cancer of Pancreas

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genzyme, a Sanofi Company

Completed

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Thyroid Cancer

United States
Karin Skov
AstraZeneca; University of Aarhus

Unknown

Danish Hypertension Prevention Project - DHYPP

Hypertension

Denmark
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Bipolar Depression

United States, Canada
University of British Columbia
AstraZeneca; CIHR Canadian HIV Trials Network

Terminated

Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients

HIV Infections | Atherosclerosis

Canada
French Innovative Leukemia Organisation
AbbVie; AstraZeneca; BeiGene; Janssen-Cilag Ltd.

Recruiting

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (FOLLOW)

CLL/SLL

France
Austin I Kim
AstraZeneca; Genentech, Inc.

Recruiting

Avo In R/R And Previously Untreated MCL

Mantle Cell Lymphoma | Refractory Lymphoma

United States
Washington University School of Medicine
AstraZeneca; Gateway for Cancer Research

Recruiting

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

United States
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca

Recruiting

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Intrahepatic Cholangiocarcinoma

Germany
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; Cancer Research UK

Recruiting

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)

Breast Cancer

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
AstraZeneca

Completed

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Neurofibromatosis Type 1 | Optic Nerve Glioma | Plexiform Neurofibroma

United Kingdom
University Hospital, Geneva
Bayer; AstraZeneca; Vifor Pharma; Labatec Pharma SA

Terminated

Improving Knowledge in Heart Failure Inpatient With Therapeutic Education (EDUC-IC)

Medication Adherence | Knowledge, Attitudes, Practice | Heart Failure With Reduced Ejection Fraction | Pharmacist-Patient Relations | Heart Failure; With Decompensation

Switzerland
European Organisation for Research and Treatment...
AstraZeneca

Active, not recruiting

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (APPLE)

NSCLC

France, Spain, Slovenia, Jordan, Poland
Centre Hospitalier Universitaire de Besancon
Eli Lilly and Company; AstraZeneca

Completed

Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients (ExeQOL)

Quality of Life

France
M.D. Anderson Cancer Center
United States Department of Defense; AstraZeneca

Terminated

Malignant Pleural Effusion With ZD6474

Lung Cancer | Pleural Effusion

United States
University Hospital, Akershus
University of Oslo; AstraZeneca; Norwegian Cancer Society

Completed

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA)

Heart Failure | Breast Cancer

Norway
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Unknown

Measuring Response to Depression Treatment

Depression

Canada
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Cancer Institute and Hospital, Chinese Academy...
AstraZeneca

Recruiting

Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data

Lung Cancer

China
German Asthma Net e.V.
Sanofi; GlaxoSmithKline; AstraZeneca; Chiesi Farmaceutici S.p.A.

Recruiting

Register Schweres Asthma - German Asthma Net e.V.

Severe Asthma

Germany
Institute of Cancer Research, United Kingdom
AstraZeneca; Cancer Research UK

Recruiting

ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

Gynaecological Cancers

United Kingdom
National Cancer Institute, Naples
AstraZeneca; University of Campania "Luigi Vanvitelli"

Recruiting

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)

Carcinoma, Non-Small-Cell Lung

Italy
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
CCTU- Cancer Theme
AstraZeneca

Recruiting

AZD6738 & Gemcitabine as Combination Therapy (ATRiUM)

Cancer

United Kingdom
University College, London
AstraZeneca; Cancer Research UK; Kidney Cancer UK

Recruiting

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Renal Cell Carcinoma

United Kingdom
Se-Hoon Lee
Roche Pharma AG; AstraZeneca

Completed

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2)

Lung Cancer

Korea, Republic of
Memorial Sloan Kettering Cancer Center
AstraZeneca; Cedars-Sinai Medical Center

Active, not recruiting

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Pancreatic Adenocarcinoma

United States
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
AstraZeneca
Parexel; Covance; Iqvia Pty Ltd; Theradex; Myriad Genetics, Inc.

Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)

Non-Germline BRCA Mutated Ovarian Cancer

Italy, Spain, Sweden, Canada, Czechia, Poland, United Kingdom, Israel, Austria, Belgium, Switzerland, Netherlands, Bulgaria, Finland, Norway, Denmark, Slovenia, Portugal
Boca Raton Regional Hospital
AstraZeneca; Ottawa Heart Institute Research Corporation

Completed

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET)

Saphenous Vein Graft Disease

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); AstraZeneca

Completed

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Institut Català d'Oncologia
AstraZeneca; BioClever 2005 S.L.; VCN Biosciences, S.L.

Active, not recruiting

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Recurrence | Head and Neck Neoplasms | Metastasis | Carcinoma, Squamous Cell of Head and Neck

Spain
AstraZeneca
Parexel; PRA Health Sciences; Q2 Solutions; Covance Laboratories, Inc

Completed

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Type 2 Diabetes

United States, Israel, Hungary, Russian Federation, Mexico, Romania, United Kingdom
Alain Algazi
AstraZeneca; Incyte Corporation

Withdrawn

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
Alison Stopeck
Eli Lilly and Company; AstraZeneca

Withdrawn

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Locally Advanced Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

United States
CCTU- Cancer Theme
AstraZeneca

Unknown

Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials (CALIBRATE)

Cancer

United Kingdom
Centre Hospitalier Universitaire de Besancon
Eli Lilly and Company; AstraZeneca

Completed

Exenatide for Stress Hyperglycemia (ExSTRESS)

Stress Hyperglycemia

France

Clinical Trials Sponsored by AztraZeneca

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations